Tuesday, March 18, 2025 | 01:09 AM ISTहिंदी में पढें
Business Standard
Notification Icon
userprofile IconSearch

CEPI to grant $14 mn for trial of Bharat Biotech's Chikungunya vaccine

The vaccine completed standard pre-clinical studies, and an optimum immune response was elicited by the adjuvant vaccine in phase-1 trials in India

CEPI to grant $14 mn for trial of Bharat Biotech's Chikungunya vaccine
Premium

Bharat Biotech's BBV87 vaccine is an inactivated whole-virion vaccine based on a strain derived from an East, Central, and South African genotype

BS Reporter Hyderabad
The Coalition for Epidemic Preparedness Innovations(CEPI) has signed an agreement to fund a consortium of Hyderabad-based vaccine maker Bharat Biotech (BBIL) and the International vaccine Institute (IVI) to fund up to $14 million to advance the development of a Chikungunya vaccine.

The consortium will be further supported with a grant of up to $2 million from the Indian Government's Ind-CEPI initiative, which will fund the setting up of manufacturing facilities for the vaccine in India, and subsequent manufacture of clinical trial material.


The investment is

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in